The Role of Osteopontin in Leukemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1008417

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

While most leukemia patients initially respond well to chemotherapy, >60% die because the disease returns as a result of the survival of leukaemia cells following treatment. We have identified a new protein, osteopontin (OPN), that may allow the survival of leukaemia cells and therefore reduce the ability of chemotherapy to erradicate disease. We seek to examine the role of OPN in leukemia with a view toward developing targetted therapies in the future.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $605,963.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cell Development, Proliferation and Death

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer biology | cancer cell biology | cell survival | haematopoiesis | leukaemia | osteopontin | prognostic factors | relapse | targeted therapy

Related Links